

Table S1: Cytotoxicity (IC₅₀, $\mu\text{M} \pm \text{SD}$) of the precursors (**1-3**) and synthesized compound (**10-12** and **16-17**) at 24 and 72 h of incubation.

Time incubation	Compound	MG-63	MCF-7	HT-29
24 h	1	18.3 \pm 1.4	>100	0.066 \pm 0.002
	2	1.23 \pm 0.06	>100	0.028 \pm 0.006
	5	1.11 \pm 0.18	8.23 \pm 0.05	4.33 \pm 1.73
	15	2.8 \pm 0.06	1.38 \pm 0.14	4.77 \pm 0.20
	16	2.7 \pm 0.04	8.81 \pm 0.21	4.16 \pm 0.15
	17	0.75 \pm 0.12	13.09 \pm 0.04	4.12 \pm 0.05
72 h	1	0.028 \pm 0.003	0.007 \pm 0.005	>100
	2	0.48 \pm 0.03	0.06 \pm 0.02	>100
	5	4.93 \pm 0.76	4.93 \pm 0.76	8.51 \pm 0.01
	9	1.82 \pm 0.18	3.97 \pm 0.23	0.26 \pm 0.07
	10	0.55 \pm 0.35	0.87 \pm 0.13	0.88 \pm 0.41
	11	4.45 \pm 3.68	4.86 \pm 0.98	2.90 \pm 0.84
	15	2.33 \pm 0.78	2.26 \pm 0.88	0.83 \pm 0.25
	16	2.34 \pm 0.25	0.26 \pm 0.08	0.65 \pm 0.02
	17	1.78 \pm 0.20	0.29 \pm 0.17	0.041 \pm 0.005

Table S2: % apoptotic cells (ratios Annexin +/- and PI +/-) at 24 h of incubation

	Compound	Concentration	Annexin - (%)	Annexin +		
				Total (%)	PI- (%)	PI+ (%)
MCF-7		Control	83.50	16.50	17.76	86.24
	1	1 μ M	75.36	24.64	91.33	8.67
	2	1 μ M	78.86	21.14	89.04	10.96
	3	1 μ M	38.69	61.04	52.87	47.13
	16	1 μ M	84.07	15.93	56.33	43.47
	17	1 μ M	83.37	16.63	40.81	59.19
	18	1 μ M	81.49	18.51	20.03	79.97
MG-63		Control	89.58	10.42	33.32	66.68
	1	1 μ M	51.44	48.56	64.62	35.38
	2	1 μ M	51.92	48.08	81.29	18.71
	3	1 μ M	38.69	61.04	52.87	47.13
	16	1 μ M	70.22	29.78	93.12	6.88
	17	1 μ M	71.33	28.66	62.35	37.65
	18	1 μ M	65.26	34.74	83.25	16.75
HT-29		Control	94.70	5.30	22.55	77.45
	1	1 μ M	94.70	5.30	22.55	77.45
	2	1 μ M	83.11	16.89	79.60	20.40
		0.1 μ M	87.47	12.53	92.01	7.99
		0.01 μ M	86.97	13.04	-	-
	3	1 μ M	52.85	48.15	11.41	88.59
		0.1 μ M	93.60	6.40	-	-
		0.01 μ M	94.10	5.90	-	-
	16	1 μ M	88.79	11.21	56.33	43.47
	17	1 μ M	88.98	11.02	40.81	59.19
	18	1 μ M	64.94	35.06	13.02	86.98
		0.1 μ M	89.29	13.71	-	-
		0.01 μ M	94.35	5.65	-	-

Table S3: % apoptotic cells (ratios Annexin) at 48 h of incubation in HT-29 cell line.

Compound	Concentration	Annexin - (%)	Annexin + (%)
2	Control	90.90	10.10
	1 μ M	87.92	12.08
	0.1 μ M	87.58	12.42
	0.01 μ M	91.20	8.80
3	Control	86.43	13.50
	1 μ M	87.92	12.08
	0.1 μ M	89.35	10.65
	0.01 μ M	91.32	8.68
18	1 μ M	43.67	56.30
	0.1 μ M	44.79	55.21
	0.01 μ M	71.14	27.86

Table S4: results (%) of cells in each cell cycle phase at 24 of incubation

	MG63			MCF7			HT-29		
	G0/G1	S	G2/M	G0/G1	S	G2/M	G0/G1	S	G2/M
1	0	0	100	0	0	100	3.1	26.02	70.85
2	0	0	100	3.76	1.80	94.63	2.15	5.62	92.29
3	55.04	11.64	34.83	73.09	7.02	19.89	59.99	10.92	29.10
16	64.07	13.90	24.29	74.03	7.85	18.13	49.45	10.48	40.07
17	67.11	13.24	21.33	76.16	8.80	15.05	62.72	14.80	22.49
18	43.16	18.41	47.03	35.00	9.38	55.63	10.42	5.03	84.55
Control	56.49	14.74	28.15	62.65	14.87	23.93	61.92	13.02	25.03




Table S5: ^1H NMR for compound **7-9**, δ in ppm (J in Hz)

	H	7	8	9
Cyclolignan	3	6.31 <i>s</i>	6.36 <i>s</i>	6.39 <i>s</i>
	6	6.99 <i>s</i>	6.95 <i>s</i>	6.95 <i>s</i>
	7	4.86 <i>d</i> (11.2)	4.92 <i>d</i> (14.0 Hz)	4.86 <i>d</i> (11.2)
	8	2.26 <i>m</i>	2.25 <i>m</i>	2.25 <i>m</i>
	9	4.02 <i>m</i> 3.63 <i>dd</i> (4.8, 12.0)	3.67 <i>m</i> 3.96 <i>m</i>	4.00 <i>m</i> 3.62 <i>dd</i> (2.4, 11.2)
	10	5.82 <i>s</i>	5.87 <i>s</i>	5.90 <i>s</i>
	12, 13	1.42 <i>s</i> ; 1.55 <i>s</i>	1.34 <i>s</i> ; 1.51 <i>s</i>	1.44 <i>s</i> ; 1.55 <i>s</i>
	2' 6'	6.20 <i>s</i>	6.27 <i>s</i>	6.24 <i>s</i>
	7'	4.31 <i>bs</i>	4.37 <i>bs</i>	4.40 <i>bs</i>
	8'	2.71 <i>dd</i> (2.0, 4.8)	2.76 <i>m</i>	2.82 <i>dd</i> (2.0, 4.4)
	10' 12'	3.76 <i>s</i>	3.74 <i>s</i>	3.75 <i>s</i>
	11'	3.71 <i>s</i>	3.70 <i>s</i>	3.72 <i>s</i>
linker				4.36 <i>m</i>
		4.04 <i>m</i>	4.02 <i>m</i>	5.09 <i>d</i> (6.8)
		3.38 <i>m</i>	3.99 <i>m</i>	5.19 <i>d</i> (6.8)
		2.10 <i>m</i>	1.36-1.89 <i>m</i>	7.10 <i>d</i> (8.0) 7.30 <i>d</i> (8.0)




Table S6: ^{13}C NMR for compound **7-9**, δ in ppm.

	C	7	8	9
Cyclolignan	1	116.5	116.7	116.5
	2	130.6	130.8	130.8
	3	106.2	106.1	105.9
	4	147.4	147.1	147.3
	5	150.3	150.0	150.2
	6	109.3	109.5	109.6
	7	68.0	67.9	68.1
	8	29.0	28.9	28.7
	9	63.7	63.9	63.9
	10	101.0	100.9	100.7
	11	99.6	99.7	99.7
	12. 13	19.5. 29.7	19.5. 29.9	19.5. 29.8
	1'	140.8	140.6	140.6
	2'6'	104.8	104.7	104.6
	3'5'	153.3	153.1	153.2
	4'	141.8	141.9	141.7
	7'	47.0	46.8	47.1
	8'	35.2	34.9	34.8
	9'	172.7	172.9	172.9
	10' 12'	59.7	59.7	59.7
	11'	60.9	60.8	61.0
linker		39.2. 63.1. 65.0	28.3. 28.8. 35.3. 38.9. 63.1. 64.9	63.4. 65.7. 125.6. 125.8. 128.2. 128.7. 136.4. 136.7




Table S7: ^1H NMR for compound **10-12**, δ in ppm (J in Hz)

H	10	11	12
2	7.21 <i>d</i> (8.0)	7.21 <i>d</i> (8.0)	7.22 <i>d</i> (8.0)
3	7.17 <i>d</i> (8.0)	7.17 <i>d</i> (8.0)	7.20 <i>d</i> (8.0)
C1-CO-OCH ₃	2.39 <i>s</i>	2.39 <i>s</i>	2.46 <i>s</i>
C4-CO-OCH ₃	2.37 <i>s</i>	2.37 <i>s</i>	2.46 <i>s</i>
5	7.71 <i>d</i> (8.8)	7.71 <i>d</i> (8.8)	7.80 <i>d</i> (8.8)
7	7.32 <i>dd</i> (1.8; 8.8)	7.32 <i>dd</i> (1.8; 8.8)	7.38 <i>dd</i> (1.8; 8.8)
8	7.66 <i>d</i> (1.8)	7.66 <i>d</i> (1.8)	7.66 <i>d</i> (1.8)
9	3.03 <i>t</i> (8)	3.03 <i>t</i> (8)	3.15 <i>t</i> (7.6)
10	2.60 <i>t</i> (8)	2.60 <i>t</i> (8)	2.78 <i>t</i> (7.6)
		3.97 <i>t</i> (6.8)	
	4.04 <i>t</i> (7.2)	1.71 <i>m</i>	5.10 <i>s</i>
	1.96 <i>m</i>	1.27 <i>m</i>	7.33 <i>d</i> (8.4)
	3.22 <i>t</i> (6.4)	1.19 <i>m</i>	7.26 <i>d</i> (8.4)
		1.48 <i>m</i>	4.47 <i>s</i>
		3.28 <i>t</i> (7.2)	




Table S8: ^{13}C NMR for compound **10-12**, δ in ppm.

C	10	11	12
1	144.7	147.2	147.5
2	118.1	117.1	117.9
3	117.2	117.4	117.1
4	144.5	147.0	147.2
4a	126.7	126.4	127.1
5	122.9	122.2	122.3
6	129.0	128.3	129.2
7	142.5	140.9	140.5
8	120.4	120.2	120.3
8a	128.3	128.0	127.9
9	34.1	35.1	35.6
10	33.1	31.5	31.2
11	177.8	177.8	177.3
-O<u>C</u>CH₃	169.9	169.6	169.4
-O<u>C</u><u>C</u>H₃	21.5	21.2	20.0
C_HOOR		27.4	31.1
	29.1	27.7	127.0
	35.5	38.4	128.7
	64.5	33.8	129.4
		64.8	133.3
			136.6




Table S9: ^1H NMR for compound **13-15**, δ in ppm (J in Hz)

H		13	14	15
MHQ	2	7.21 <i>d</i> (8.0)	7.21 <i>d</i> (8.0)	7.22 <i>d</i> (8.0)
	3	7.17 <i>d</i> (8.0)	7.17 <i>d</i> (8.0)	7.18 <i>d</i> (8.0)
	5	4.90 <i>s</i>	7.78 <i>d</i> (8.8)	7.78 <i>d</i> (8.0)
	7	1.19 <i>s</i>	7.40 <i>dd</i> (2.0; 8.8)	7.39 <i>dd</i> (1.8; 8.0)
	8	0.43 <i>s</i>	7.64 <i>d</i> (2.0)	7.66 <i>d</i> (1.8)
	9	7.12 <i>d</i> (8.0)	3.11 <i>t</i> (7.6)	3.14 <i>t</i> (7.6)
	10	7.14 <i>d</i> (8.0)	2.66 <i>t</i> (7.6)	2.82 <i>t</i> (7.6)
	-OAc	2.44 <i>s</i> ; 2.45 <i>s</i>	2.44 <i>s</i> ; 2.45 <i>s</i>	2.45 <i>s</i>
linker		4.02 <i>m</i> 1.80 <i>m</i> 1.25 <i>m</i>	4.02 <i>m</i> 3.99 <i>m</i> 1.25-1.80 <i>m</i>	5.19 <i>d</i> (10.4) 5.09 <i>d</i> (10.4) 7.24 <i>d</i> (7.6) 7.10 <i>d</i> (7.6)
Cyclolignan	3	6.38 <i>s</i>	6.38 <i>s</i>	6.39 <i>s</i>
	6	6.97 <i>s</i>	6.97 <i>s</i>	6.95 <i>s</i>
	7	4.90 <i>d</i> (10.8)	4.90 <i>d</i> (10.8)	4.75 <i>d</i> (10.8)
	8	2.17 <i>m</i>	2.17 <i>m</i>	2.25 <i>m</i>
	9	4.04 <i>m</i> 3.68 <i>dd</i> (4.4; 11.2)	4.04 <i>m</i> 3.68 <i>dd</i> (4.4; 11.2)	3.96 <i>t</i> (11.6) 3.63 <i>dd</i> (3.6; 11.6)
	10	5.89 <i>s</i>	5.89 <i>s</i>	5.90 <i>s</i>
	12, 13	1.49 <i>s</i> ; 1.55 <i>s</i>	1.49 <i>s</i> ; 1.55 <i>s</i>	1.34 <i>s</i> ; 1.51 <i>s</i>
	2', 6'	6.25 <i>s</i>	6.25 <i>s</i>	6.24 <i>s</i>
	7'	4.72 <i>d</i> (10.2)	4.72 <i>d</i> (10.2)	4.74 <i>d</i> (10.8)
	8'	2.78 <i>m</i>	2.78 <i>m</i>	2.25 <i>m</i>
	10', 12'	3.78 <i>s</i>	3.78 <i>s</i>	3.74 <i>s</i>
	11'	3.83 <i>s</i>	3.83 <i>s</i>	3.79 <i>s</i>




Table S10: ^{13}C NMR for compound **13-15**, δ in ppm.

		13	14	15
MHQ	C			
	1	147.0	147.2	147.5
	2	117.9	118.1	117.9
	3	117.2	117.4	117.1
	4	147.0	147.0	147.2
	4a	126.3	126.4	127.1
	C ₁ CO-OCH ₃	169.3; 21.0	169.6; 21.3	169.4; 20.0
	C ₄ CO-OCH ₃	169.3; 21.0	169.6; 21.2	169.6; 20.0
	5	122.0	122.2	122.3
	6	128.4	128.3	129.2
	7	140.5	140.9	140.5
	8	120.3	120.2	120.3
	8a	128.0	128.0	127.9
	9	35.6	35.1	35.6
	10	31.6	31.5	31.2
	11	122.0	122.2	122.3
Cyclolignan	linker	35.2; 65.8; 66.3	65.0; 64.6; 35.1 28.7; 25.7; 25.6	136.2; 135.4; 128.7; 128.7; 67.2; 66.9
	1	126.3	126.6	128.0
	2	130.8	131.1	130.8
	3	105.1	105.0	104.7
	4	147.1	147.2	147.0
	5	150.0	147.2	146.9
	6	109.5	109.7	109.5
	7	67.9	68.1	67.8
	8	29.0	35.8	34.9
	9	63.7	63.3	62.9
	10	101.0	99.9	101.0
	11	99.6	98.7	99.6
	12. 13	30.0; 19.6	30.1; 19.8	29.9; 19.3
	1'	137.3	138.2	140.5
	2'6'	106.4	106.4	106.1
	3'5'	152.9	153.3	153.1
	4'	137.9	137.7	136.8
	7'	46.8	47.0	46.6
	8'	68.0	68.1	67.8
	9'	172.1	173.1	172.4
	10' 12'	56.2	56.4	60.8
	11'	60.8	61.1	62.9




Table S11: ^1H NMR for compound **16-18**, δ in ppm (J in Hz)

H		16	17	18
MHQ	2	7.21 <i>d</i> (8.0)	7.20 <i>d</i> (8.0)	7.22 <i>d</i> (8.0)
	3	7.18 <i>d</i> (8.0)	7.17 <i>d</i> (8.0)	7.18 <i>d</i> (8.0)
	5	7.78 <i>d</i> (8.0)	7.78 <i>d</i> (9.0)	7.78 <i>d</i> (8.0)
	7	7.39 <i>dd</i> (1.8; 8.0)	7.39 <i>dd</i> (0.8; 9.0)	7.39 <i>dd</i> (1.8; 8.0)
	8	7.64 <i>d</i> (1.8)	7.66 <i>d</i> (0.8)	7.66 <i>d</i> (1.8)
	9	3.08 <i>t</i> (8.0)	3.01 <i>t</i> (7.6)	3.13 <i>t</i> (7.6)
	10	2.66 <i>t</i> (8.0)	2.67 <i>t</i> (7.6)	2.74 <i>t</i> (7.6)
	-OAc	2.43 <i>s</i> ; 2.45 <i>s</i>	2.43 <i>s</i> ; 2.45 <i>s</i>	2.44 <i>s</i> ; 2.45 <i>s</i>
linker		4.06 <i>t</i> (6.0) 1.88 <i>m</i> 3.98 <i>t</i> (4.0)	4.02 <i>t</i> (6.8) 1.54 <i>m</i> 1.46 <i>m</i> 1.23 <i>m</i> 1.20 <i>m</i> 3.97 <i>m</i>	5.08 <i>d</i> (10.8) 5.06 <i>d</i> (10.8) 7.24 <i>d</i> (7.6) 7.10 <i>d</i> (7.6) 5.09 <i>m</i>
Cyclolignan	3	6.47 <i>s</i>	6.50 <i>s</i>	6.61 <i>s</i>
	6	6.87 <i>s</i>	6.87 <i>s</i>	6.88 <i>s</i>
	7	7.33 <i>s</i>	7.41 <i>s</i>	7.38 <i>s</i>
	9	9.59 <i>s</i>	9.59 <i>s</i>	9.59 <i>s</i>
	10	5.98 <i>s</i>	5.98 <i>s</i>	6.00 <i>s</i>
	2, 6'	6.21 <i>s</i>	6.20 <i>s</i>	6.20 <i>s</i>
	7'	4.59 <i>d</i> (4.0)	4.59 <i>d</i> (3.2)	4.58 <i>d</i> (4)
	8'	2.82 <i>d</i> (3.6)	3.97 <i>m</i>	4.04 <i>d</i> (4)
10', 12'		3.73 <i>s</i>	3.73 <i>s</i>	3.76 <i>s</i>
11'		3.75 <i>s</i>	3.76 <i>s</i>	3.81 <i>s</i>




Table S12: ^{13}C NMR for compound **16-18**, δ in ppm.

C		16	17	18
MHQ	1	144.3	145.5	144.3
	2	117.9	119.4	118.1
	3	117.1	118.6	117.4
	4	144.0	145.5	144.0
	4a	126.4	129.7	122.2
	C ₁ CO-OCH ₃	169.4; 21.0	170.9; 22.6	169.5; 21.3
	C ₄ CO-OCH ₃	169.4; 21.0	170.9; 22.6	169.6; 21.4
	5	122.0	123.5	122.2
	6	128.0	129.3	128.0
	7	147.4	141.0	137.1
	8	120.1	121.7	120.2
	8a	127.7	129.7	182.1
	9	31.1	37.2	35.6
	10	27.7	32.8	31.1
	11	171.6	173.2	171.6
linker				133.7
		35.5		128.3
		60.7	25.2 28.4 38.0	127.8
		61.6	39.0 63.9 65.1	133.1
				66.0
Cyclolignan				66.5
	1	125.0	126.7	125.3
	2	133.1	135.3	133.8
	3	110.0	111.6	117.1
	4	150.5	151.9	150.4
	5	108.9	151.9	150.1
	6	147.4	110.4	110.0
	7	133.7	146.9	145.6
	8	191.2	134.8	133.1
	9	101.8	192.8	191.2
	10	125.0	103.3	101.8
	1'	137.0	35.6	135.7
	2', 6'	104.8	107.0	104.8
	3', 5'	153.2	154.7	153.2
	4'	139.4	138.7	136.9
	7'	46.4	47.8	46.4
	8'	44.7	46.1	44.4
	9'	172.4	174.2	172.4
	10', 12'	60.7	57.7	56.1
	11'	56.1	62.3	60.7





Figure S1: Docking complexes of precursors **3** and **4** in the colchicine site of tubulin. GTP, the inhibitors, and those residues that interact with the inhibitors via hydrogen bonds are shown atomistically. The two protomers tubulin and are shown in yellow and purple, respectively




Figure S2: ¹H and ¹³C NMR spectra for compound 7




Figure S3: ¹H and ¹³C NMR spectra for compound **8**




Figure S4: ¹H and ¹³C NMR spectra for compound **9**




Figure S5: ^1H and ^{13}C NMR spectra for compound **10**




Figure S6: ¹H and ¹³C NMR spectra for compound 11




Figure S7: ¹H and ¹³C NMR spectra for compound **12**





Figure S8: ¹H and ¹³C NMR spectra for compound **13**




Figure S9: ¹H and ¹³C NMR spectra for compound **14**




Figure S10: ¹H and ¹³C NMR spectra for compound **15**




Figure S11: ¹H and ¹³C NMR spectra for compound **16**




Figure S12: ^1H and ^{13}C NMR spectra for compound 17





Figure S13: ^1H and ^{13}C NMR spectra for compound **18**